18 and older, any sex, with Glaucoma. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Time of First Cannula in Until Satisfactory Stent Placement and Cannula OutPrimary· up to 1 hour
Group
Value
95% CI
Conventional Microscope
2.55
± 1.36
NGENUITY
3.06
± 2.17
Number of Trabecular Meshwork Piercing Attempts Needed to Place StentSecondary· up to 1 hour
Group
Value
95% CI
Conventional Microscope
1.50
± 0.94
NGENUITY
1.53
± 0.92
Number of Anterior Chamber Entry and Reentry Attempts During Stent PlacementSecondary· up to 1 hour
Group
Value
95% CI
Conventional Microscope
1.14
± 0.36
NGENUITY
1.13
± 0.35
Number of Microscope Focus or Position Readjustments Needed During Stent PlacementSecondary· up to 1 hour
Group
Value
95% CI
Conventional Microscope
1.43
± 1.28
NGENUITY
1.93
± 1.79
Change in Attending Questionnaire ScoreSecondary· Up to 5 minutes
Providers rate their comfort, visibility, image quality, focus, depth perception, staff engagement, teaching and level of confidence in using the system and system performance. Ratings are on a Likert scale of 1 to 5. Higher scores correspond to excellent ratings, higher confidence in using the system, and better system performance; for Scope Preference only, lower numbers (either group) correspond to a preference for NGenuity visualization.
Comfort
Group
Value
95% CI
Conventional Microscope
3.14
± 0.53
NGENUITY
3.93
± 0.80
Visibility
Group
Value
95% CI
Conventional Microscope
3.57
± 0.85
NGENUITY
4.53
± 0.64
Image Quality
Group
Value
95% CI
Conventional Microscope
3.14
± 0.77
NGENUITY
4.6
± 0.74
Focus
Group
Value
95% CI
Conventional Microscope
3.14
± 0.66
NGENUITY
4.0
± 1.25
Depth Perception
Group
Value
95% CI
Conventional Microscope
2.93
± 0.73
NGENUITY
4.67
± 0.62
Staff Engagement
Group
Value
95% CI
Conventional Microscope
3.36
± 0.50
NGENUITY
4.27
± 0.80
Teaching
Group
Value
95% CI
Conventional Microscope
3.29
± 0.73
NGENUITY
4.67
± 0.62
En Face Confidence
Group
Value
95% CI
Conventional Microscope
3.43
± 0.51
NGENUITY
4.07
± 0.96
Change in Fellow Questionnaire ScoreSecondary· Up to 5 minutes
Providers rate their comfort, visibility, image quality, focus, depth perception, staff engagement, teaching and level of confidence in using the system and system performance. Ratings are on a Likert scale of 1 to 5. Higher scores correspond to excellent ratings, higher confidence in using the system, and better system performance; for Scope Preference only, lower numbers (either group) correspond to a preference for NGenuity visualization.
Comfort
Group
Value
95% CI
Conventional Microscope
4.21
± 0.89
NGENUITY
4.20
± 0.56
Visibility
Group
Value
95% CI
Conventional Microscope
4.21
± 0.80
NGENUITY
4.60
± 0.83
Image Quality
Group
Value
95% CI
Conventional Microscope
4.21
± 0.80
NGENUITY
4.60
± 0.83
Focus
Group
Value
95% CI
Conventional Microscope
3.93
± 0.83
NGENUITY
4.40
± 0.91
Depth Perception
Group
Value
95% CI
Conventional Microscope
4.29
± 0.61
NGENUITY
4.73
± 0.59
Staff Engagement
Group
Value
95% CI
Conventional Microscope
3.57
± 0.94
NGENUITY
4.73
± 0.59
Teaching
Group
Value
95% CI
Conventional Microscope
4.00
± 0.78
NGENUITY
4.80
± 0.56
En Face Confidence
Group
Value
95% CI
Conventional Microscope
4.00
± 0.88
NGENUITY
4.33
± 0.82
Sponsor's own description
To compare the potential efficiency and educational value of using NGENUITY (3D camera system, FDA approved for this indication) vs the conventional microscope for Hydrus microstent placement by new users.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
NCT07217678 — Biomarkers of Ocular Surface Damage in the Setting of Topical Ocular Hypotensive Medication Use
· Phase 4
· recruiting
NCT07145073 — Repetitive Transcranial Alternating Current Stimulation (rtACS) for the Treatment of Optic Neuropathies
· NA
· recruiting
NCT07209410 — Evaluating Injection With the Use of Brimonidine Tartrate Ophthalmic 0.025% on Patients Using Netarsudil 0.02%/Latanopro
· Phase 4
· recruiting
Other Stanford University trials
Trials by the same sponsor.
NCT05945147 — Ketamine and Midazolam Infusions for CRPS: Feasibility Study
· Phase 2
· withdrawn
NCT04225949 — Patients Understanding of PROM Graphs
· NA
· withdrawn
NCT06273098 — School-Based Bladder Health Intervention
· NA
· withdrawn
NCT04652635 — Management of Nailbed Injuries
· NA
· withdrawn
NCT05443503 — Stanford Spine Keeper - Managing Your Low Back Pain
· NA
· suspended
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Stanford University
Last refreshed: 17 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05529966.